|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Who is ARTERA?
|
Andre Esteva, Ph.D.
Andre Esteva, CEO of Artera Inc. joins Alicia Morgans to discuss Artera and its artificial intelligence-derived digital pathology-based biomarker test for prostate cancer that enables prostate cancer personalized therapy.
|
|
|
|
|
|
|
|
|
|
|
|
Beyond Genomics: AI Informing Decision Making in Prostate Cancer
|
Ashley Ross, MD, Ph.D.
Alicia Morgans and Ashely Ross discuss the current clinical landscape of how risk is defined in localized prostate cancer, highlighting a novel artificial intelligence-derived digital pathology-based biomarker test for prostate cancer developed by Artera.
|
|
|
|
|
|
|
|
|
|
|
| Prostate Cancer Therapy Personalization via Multi-Modal Deep Learning on Randomized Phase III Clinical Trials
|
| Andre Esteva, Jean Feng, Douwe van der Wal et al.
|
| Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient's optimal therapy is a challenge, where oncologists must select a therapy with the highest likelihood of success and the lowest likelihood of toxicity.
|
|
|
|
|
|
| Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology
|
| Jonathan Tward, MD, Ph.D., FASTRO
|
| Jonathan Tward discusses prostate cancer risk stratification using multimodal deep learning with digital histopathology, within the context of NRG Oncology phase III trials.
|
|
|
|
|
|
| External Validation of a Digital Pathology-Based AI Model Predicting Metastasis and Death in High and Very High Risk Men on The NRG/RTOG 9902 Phase III Trial
|
| Ashley E. Ross, MD, Ph.D.
|
| Ashley Ross presents the results of external validation of a digital pathology-based artificial intelligence (AI) model predicting metastasis and death in high and very high-risk men from the NRG/RTOG 9902 phase III trial.
|
|
|
|
|
|
| An AI-Derived Digital Pathology-Based Biomarker to Predict the Benefit of ADT in Localized Prostate Cancer with Validation in NRG/RTOG 9408
|
| Daniel E. Spratt, MD
|
| Daniel Spratt discusses an AI-derived digital pathology-based biomarker to predict the benefit of ADT in localized prostate cancer with validation in NRG/RTOG 9408. This study represents the successful validation in a phase III randomized trial of the first predictive biomarker of ADT benefit with radiotherapy in localized intermediate-risk prostate cancer using a novel AI-derived digital pathology-based platform.
|
|
|
|
|
|
| Artificial Intelligence in Urologic Oncology |
| Andrew Hung, MD
|
| Andrew Hung discusses artificial intelligence in urologic oncology. Dr. Hung started his presentation by highlighting several important definitions and notes that over the last several years, there has been a drastic increase in the number of artificial intelligence publications in the urology literature, with nearly 180 publications in 2021.
|
|
|
|
|
|
